These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10357695)

  • 21. Bone loss in thyroid disease: role of low TSH and high thyroid hormone.
    Abe E; Sun L; Mechanick J; Iqbal J; Yamoah K; Baliram R; Arabi A; Moonga BS; Davies TF; Zaidi M
    Ann N Y Acad Sci; 2007 Nov; 1116():383-91. PubMed ID: 18083940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen.
    Schneider DL; Barrett-Connor EL; Morton DJ
    JAMA; 1994 Apr; 271(16):1245-9. PubMed ID: 7848399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thyroid Hormone Diseases and Osteoporosis.
    Delitala AP; Scuteri A; Doria C
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32268542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Impact of thyroid diseases on bone].
    Tsourdi E; Lademann F; Siggelkow H
    Internist (Berl); 2018 Jul; 59(7):661-667. PubMed ID: 29744522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The risk factors and bone mineral density in women on long-term levothyroxine treatment].
    López Alvarez MB; Hawkins F; Rigopoulou D; Martínez G; Jodar E; Estenoz J; Ortuño B; Arnaiz F
    Med Clin (Barc); 1999 Jan; 112(3):85-9. PubMed ID: 10074614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.
    Biondi B; Cooper DS
    Thyroid; 2010 Feb; 20(2):135-46. PubMed ID: 20151821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thyroid hormone excess and osteoporosis.
    Leb G; Warnkross H; Obermayer-Pietsch B
    Acta Med Austriaca; 1994; 21(2):65-7. PubMed ID: 7527991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk Factors for Predicting Osteoporosis in Patients Who Receive Thyrotropin Suppressive Levothyroxine Treatment for Differentiated Thyroid Carcinoma.
    Soydal Ç; Özkan E; Nak D; Elhan AH; Küçük NÖ; Kır MK
    Mol Imaging Radionucl Ther; 2019 Jun; 28(2):69-75. PubMed ID: 31237137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma.
    Kim MK; Yun KJ; Kim MH; Lim DJ; Kwon HS; Song KH; Kang MI; Baek KH
    Bone; 2015 Feb; 71():101-5. PubMed ID: 25445448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
    Marcocci C; Golia F; Vignali E; Pinchera A
    J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of sensitive TSH assay to determine optimal thyroid hormone therapy and avoid osteoporosis.
    Wartofsky L
    Annu Rev Med; 1991; 42():341-5. PubMed ID: 2035978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thyrotropin, Hyperthyroidism, and Bone Mass.
    Kim SM; Ryu V; Miyashita S; Korkmaz F; Lizneva D; Gera S; Latif R; Davies TF; Iqbal J; Yuen T; Zaidi M
    J Clin Endocrinol Metab; 2021 Nov; 106(12):e4809-e4821. PubMed ID: 34318885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low bone mineral density is related to high physiological levels of free thyroxine in peri-menopausal women.
    van Rijn LE; Pop VJ; Williams GR
    Eur J Endocrinol; 2014 Mar; 170(3):461-8. PubMed ID: 24336745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study.
    Sugitani I; Fujimoto Y
    Surgery; 2011 Dec; 150(6):1250-7. PubMed ID: 22136848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thyroid hormones: beneficial or deleterious for bone?
    Lakatos P
    Calcif Tissue Int; 2003 Sep; 73(3):205-9. PubMed ID: 14667131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A clinical and therapeutic approach to thyrotoxicosis with thyroid-stimulating hormone suppression only.
    Papi G; Pearce EN; Braverman LE; Betterle C; Roti E
    Am J Med; 2005 Apr; 118(4):349-61. PubMed ID: 15808130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperthyroid levels of TSH correlate with low bone mineral density: the HUNT 2 study.
    Svare A; Nilsen TI; Bjøro T; Forsmo S; Schei B; Langhammer A
    Eur J Endocrinol; 2009 Nov; 161(5):779-86. PubMed ID: 19671706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer.
    Do Cao C; Wémeau JL
    Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S47-52. PubMed ID: 26826483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyroid Dysfunction in Periand Postmenopausal Women-Cumulative Risks.
    Frank-Raue K; Raue F
    Dtsch Arztebl Int; 2023 May; 120(18):311-316. PubMed ID: 37013812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyroid hormone use and bone mineral density in elderly men.
    Schneider DL; Barrett-Connor EL; Morton DJ
    Arch Intern Med; 1995 Oct; 155(18):2005-7. PubMed ID: 7575055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.